Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Other Non-Current Liabilities of $3.5 million for Q4 2025, down 60.95% on a QoQ basis from $9.0 million in Q4 2024, and down 60.95% year-over-year from $9.0 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Other Non-Current Liabilities data on file, last reported at $3.5 million in Q4 2025.

  • In Q4 2025, Other Non-Current Liabilities fell 60.95% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (down 60.95% YoY), while the FY2025 annual figure was $3.5 million, changed N/A from the prior year.
  • Other Non-Current Liabilities declined to $3.5 million in Q4 2025, from $9.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $9.0 million in Q4 2024 and bottomed at $3.5 million in Q4 2025.
  • A 3-year average of $5.9 million and a median of $5.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 72.85% — and 2025, when it plunged 60.95%.
  • Year by year, Other Non-Current Liabilities stood at $5.2 million in 2023, then surged by 72.85% to $9.0 million in 2024, then plunged by 60.95% to $3.5 million in 2025.
  • The last three Other Non-Current Liabilities figures came in at $3.5 million (Q4 2025), $9.0 million (Q4 2024), and $5.2 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 3.52 Mn
Dec 31, 2024 9.01 Mn
Dec 31, 2023 5.21 Mn